Skip Navigation



Annals of Oncology Advance Access published online on April 13, 2007
Annals of Oncology, doi:10.1093/annonc/mdm083
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/6/1064    most recent
mdm083v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eymard, J-C
Right arrow Articles by Joly, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eymard, J-C
Right arrow Articles by Joly, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

J-C Eymard1,*, F Priou2, A Zannetti3, A Ravaud4, D Lepillé5, P Kerbrat6, P Gomez7, B Paule8, D Genet9, P Hérait10, E Ecstein-Fraïssé11 and F Joly12

1 Institut Jean-Godinot, Reims
2 Centre Hospitalier Départemental, La Roche sur Yon
3 Clinique du Parc, Cholet
4 Institut Bergonié, Bordeaux
5 Clinique Pasteur, Evreux
6 Centre Eugène Marquis, Rennes
7 Centre Frédéric Joliot, Rouen
8 Hôpital Henri-Mondor, Créteil
9 Centre Hospitalier Universitaire Dupuytren, Limoges
10 Soisy-sous-Montmorency
11 Sanofi-Aventis, Paris
12 Centre Jean-François Baclesse, Caen, France

* Correspondence to: Dr J.-C. Eymard, Institut Jean-Godinot, 51056 Reims, France. Tel: +33-3-26-50-44-44; Fax: +33-3-26-50-44-49; E-mail: jc.eymard{at}reims.fnclcc.fr

Background: Docetaxel (Taxotere®)-based regimens are the new standard therapy in advanced hormone-refractory prostate cancer (HRPC). A synergistic activity has been shown with docetaxel in combination with estramustine in vitro; however, the benefit of this combination remains controversial in clinical practice. We assessed the activity and safety of docetaxel alone and docetaxel–estramustine in HRPC.

Patients and methods: Patients (n = 92) with metastatic HRPC and rising prostate-specific antigen (PSA) while receiving androgen suppression were randomized to 3-weekly treatment with either docetaxel 75 mg/m2, day 1 (D), or docetaxel 70 mg/m2, day 2, plus oral estramustine 280 mg twice daily, days 1–5 (DE).

Results: Ninety-one patients were treated (DE 47, D 44). A PSA response occurred in 68% (primary endpoint met) and 30% of patients, respectively. Median PSA response duration was 6.0 months in both groups. Median time to progression was 5.7 and 2.9 months, and median survival was 19.3 and 17.8 months in the DE and D arms, respectively. Hematologic and non-hematologic toxic effects were mild and similar in both arms. One patient in each group withdrew due to toxicity. Quality of life was similar in both groups.

Conclusion: Combining estramustine with docetaxel in this schedule is an active and well-tolerated treatment option in HRPC.

docetaxel, estramustine, hormone-refractory prostate cancer, randomized phase II

Received for publication September 10, 2006. Revision received February 4, 2007. Accepted for publication February 6, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
S. Naito, T. Tsukamoto, H. Koga, T. Harabayashi, Y. Sumiyoshi, S. Hoshi, and H. Akaza
Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 365 - 372.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.